Grace Therapeutics, Inc. (GRCE) is set to receive a key FDA decision today, April 23, 2026, on its lead drug candidate GTx-104, an investigational intravenous formulation of nimodipine developed for patients with aneurysmal subarachnoid hemorrhage.
Aneurysmal subarachnoid hemorrhage (aSAH) is a rare but life-threatening form of stroke caused by bleeding on the surface of the brain following the rupture of an aneurysm. It accounts for roughly 5% of all strokes, with an estimated 42,500 patients treated annually in U.S. hospitals. The current standard of care is oral nimodipine, administered for up to 21 days, but its use is often complicated by low blood pressure, inconsistent absorption, and challenges in patients who are unconscious or unable to swallow.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.